Data-driven insights
Proven results
Patient care
People often carry genetic mutations known as cancer susceptibility genes, which increase their likelihood of developing certain cancers.
In the UK will be diagnosed with cancer.
Are linked to a hereditary genetic variant.
Increase your risk of developing cancer.
People often carry genetic mutations known as cancer susceptibility genes, which increase their likelihood of developing certain cancers.
In the UK will be diagnosed with cancer.
Are linked to a hereditary genetic variant.
Increase your risk of developing cancer.
If you are diagnosed with cancer, knowing hereditary genetic risk can guide the deployment of effective cancer therapies.
Hereditary cancer testing gives your healthcare provider in-depth insights into your cancer’s biology, aiding the development of highly personalised treatment plans.
Specific genetic mutations increase the risk of developing other types of cancer. Early detection of these risks enables enhanced surveillance and preventive strategies for secondary cancers, improving treatment outcomes.
When a genetic mutation is identified, family members may also develop cancer—in this case, they can be tested and, if necessary, undergo early screening or preventive measures.
Genetic testing for cancer susceptibility helps you take control of your health. Testing can lead to earlier interventions, regular screenings, or life-saving preventive measures.
Patient completes Requisition and Consent Form as well as Family History Questionnaire
Saliva Sample Kit sent to patient
Saliva Sample sent to local UK lab
Susceptibility Cancer Testing commences
Report sent to your Physician
Genetic Counselling if report positive for susceptibility genes
There are multiple panels you can choose from depending on the type of cancer you have. Read more below to select the most appropriate one, or discuss with your doctor if unsure.
Personal details for personalised reporting
There are multiple panels you can choose from depending on the type of cancer you have. Read more below to select the most appropriate one, or discuss with your doctor if unsure.
Sample preparation & testing
Once all the paperwork is complete, we will send you a kit to insert your saliva sample; the kit has pre-paid postage for you to post at your convenience. Testing commences immediately when the lab receives your sample kit, and results will be ready in approximately 15 days.
Report & Consultation
Once your report is ready, your doctor will receive a copy, and so will you. If you are a carrier of any of the susceptibility genes, we will arrange for a genetic counsellor to contact you to discuss the implications and support you might require, as well as that of your family members. There is no additional cost for the genetic counsellor appointment.
Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer. JAMA. 2011;306(14):1557–1565. doi:10.1001/jama.2011.1456
The STRIPAK Complex Regulates the Hippo Kinase Cascade. Cancer Discov 1 February 2020; 10 (2): OF12. https://doi.org/10.1158/2159-8290.CD-RW2019-187
Antonis C. Antoniou, Ph.D., Silvia Casadei, Ph.D., Tuomas Heikkinen, Ph.D., et. al. Breast-Cancer Risk in Families with Mutations in PALB2.N Engl J Med 2014;371:497-506.DOI:10.1056/NEJMoa1400382.VOL.371 NO.6
Southey MC, Goldgar DE, Winqvist R, Pylkäs K, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5. PMID: 27595995; PMCID: PMC5200636.
Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel). 2021 Jan 15;13(2):300. doi: 10.3390/cancers13020300. PMID: 33467526; PMCID: PMC7830023.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122. PMID: 16236738.
Kriege, M., Hollestelle, A., Jager, A. et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer 111, 1004–1013 (2014). https://doi.org/10.1038/bjc.2014.306
Kathleen E. Malone et al., Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2. JCO 28, 2404-2410(2010).DOI:10.1200/JCO.2009.24.2495
Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, Rosty C, Leggett B, Giles GG, Goldblatt J, Macrae FA, Parry S, Kalady MF, Baron JA, Ahnen DJ, Marchand LL, Gallinger S, Haile RW, Newcomb PA, Hopper JL, Jenkins MA. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 Feb 20;105(4):274-9. doi: 10.1093/jnci/djs525. Epub 2013 Feb 5. PMID: 23385444; PMCID: PMC3576323.
Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaïti-Pellié C, Frébourg T; French LFS working group. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008 Aug;45(8):535-8. doi: 10.1136/jmg.2008.057570. Epub 2008 May 29. PMID: 18511570.
Superior Panel Performance
SNVs - 100% Sensitivity; 99.99% Specificity; PPV >97%
Indels 100% Sensitivity
CNVs97.6% Sensitivity
Variant interpretation based on MANE transcript and in line with ACMG, ACGS, and CanVIG-UK Gene Specific Recommendations, reported as Pathogenic and Likely Pathogenic
Genes are included in Genomics England's Test Directory
Highest Quality Assurance with ISO15189:2022 UKAS accreditation; GENQA participant
